| Name | Title | Contact Details |
|---|
LearnWright is a Potomac, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The DHA is a joint, integrated Combat Support Agency that enables the Army, Navy, and Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime. The DHA supports the delivery of integrated, affordable, and high quality health services to 9.5 million Military Health System beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS. The DHA oversees the delivery of health care services like the TRICARE Health Plan, pharmacy, public health, and health information technology. DHA carries out these operations using a global health care network of military and civilian medical professionals and more than 400 military hospitals and clinics. This network strengthens the delivery of health care to MHS beneficiaries by merging proven clinical and business practices and emphasizing the experience of the patient. Exciting changes are taking place as we are in the process of reorganizing how we manage the military`s medical centers, hospitals and clinics around the world, shifting administration and management responsibility for these facilities from the Army, Navy and Air Force to the Defense Health Agency. A single integrated system will support improvements to the readiness of our operational and medical forces to meet our missions around the world, while providing outstanding care to all of those who depend on us, on the battlefield and at home.
Clinical Innovations develops, manufactures and markets state-of-the-art medical devices that improve healthcare outcomes for clinicians and their patients worldwide. With particular emphasis on healthcare solutions for women and their infants, Clinical Innovations employs high quality standards in every aspect of business to make advancements in technology and bring innovative ideas to life.
Orchard Manor Inc is a Medina, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.